ADC Therapeutics (ADCT) Interest Expenses (2020 - 2026)

ADC Therapeutics (ADCT) has reported Interest Expenses for 7 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses rose 0.97% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (down 70.8% YoY) and the FY2025 annual result came in at $251.0 million, up 14.16% from the prior year.
• Interest Expenses climbed to $12.3 million in Q1 2026 per ADCT's latest filing, from -$24.2 million in the prior quarter.
• Over the last five years, Interest Expenses for ADCT reached as high as $13.4 million in Q3 2025 and fell as low as -$24.2 million in Q4 2025.
• A 5-year average of $7.4 million and a median of $11.9 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses jumped 315.37% — and 2023, when it sank 654.06%.
• Year by year, Interest Expenses stood at $3.3 million in 2022, then plunged by 654.06% to -$18.0 million in 2023, then surged by 166.11% to $11.9 million in 2024, then sank by 302.63% to -$24.2 million in 2025, then jumped by 151.13% to $12.3 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $12.3 million, -$24.2 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.